Yesterday a blustery nor'easter pounded us here on Fernandina Beach with high winds and flooding rain, One moment I felt fine, the next weak and gagging back dry heaves--or I found myself racing from one toilet or another trying to stay in front of seemingly endless diarrhea. So much to do: unpack, drain the pool,
Three steps forward and two steps back; I have a lot of good news, with a touch of bad. I need to keep this short. Spent fourth day here at U of Iowa hospital. Felt remarkably good. I spent several hours--along with doctors and other BMT team members--trying to get a handle on what has
I'm still groggy after taking in ten bags of stem cells and two liters of saline to wash it all down. I'm sure my posts will start getting shorter. But while I still can, I wanted to review the last few days. Decisions have been made. Here's why. Monday I shared my surprise when my
Today's the big day. I tell Dr. Tricot my decision: to go ahead and commit to a tandem stem cell transplant, stick with the original plan--one and done--or wait and see; if he'll agree to split the difference and decide whether to proceed in two or three months. I even launched an informal survey via
I was ready; mentally prepared to start stem cell transplant journey yesterday. I wasn't prepared for the round-house curve ball he tossed me first thing. I shared how disappointed Dr. Tricot was with two and a half months of induction therapy two weeks ago: "Apparently my current therapy combination of Cytoxan, carfilzomib (Kyprolis) and dex
I'm going to delay posting details about my discussion yesterday with Dr. Roy about whether to transplant or not to transplant until Friday. Last evening's Myeloma Cure Panel discussion is an ABSOLUTE MUST-LISTEN for any myeloma patient that has only been treated for one year or less. That may be limiting things too much. I
Sites like this one often share statistical data revealed to us through clinical studies. On the surface it seems simple enough. But things aren't always what they seem. Let me explain. Most all of the news in myeloma research these days confirms the OS advantage of achieving a complete response (CR). Logically this makes sense;
Most multiple myeloma patients under the age of 75--or sometimes even older--are faced with fateful decisions of if and when to undergo a stem cell transplant. An autologous stem cell transplant (SCT) is still the standard of care for patients who are healthy enough to undergo the procedure. They have become surprisingly safe and reliable.